Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation *

Other

Full Name LEAVE THIS BLANK

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

You will be granted access to your Celltelligence Library to view the full article after sign up.

RETURN TO HOME

Autologous, CAR-T, CD19

April 19, 2022

Could Yescarta in r/r FL Receive a CHMP Positive Opinion This Week?

Here is a brief preview of this blast: On Tuesday, April 19, the CHMP agenda for April was released. Of note, Yescarta in r/r FL after three or more lines of systemic therapy has been listed as for adoption under ‘Type II variations - variation of therapeutic indication’.

About The Author

Mark McCully, PhD

Senior Content Lead

Mark McCully, PhD is the Content Lead for Celltelligence covering the dynamic and rapidly evolving cell therapy space. Mark regularly attends large and small cell therapy scientific meetings to build upon his decade of oncology R&D experience. To that end, Mark previously worked on numerous consulting projects for large cap pharma and emerging biotech to help characterize the ever-changing landscape.